



RNS Number : 0165C
EKF Diagnostics Holdings PLC
16 June 2021

EKF Diagnostics Holdings plc
("EKF", the "Company" or the "Group")

Change of Adviser

EKF Diagnostics Holdings plc (AIM: EKF), the AIM-listed point-of-care business, announces the appointment of Investec Bank plc as joint corporate broker, with immediate effect to work alongside its existing nominated adviser and broker, N+1 Singer.

Julian Baines, CEO of EKF, commented:

"We outlined at our AGM last month a strategy to deliver significant earnings growth over the next 3 to 4 years and we are delighted to have the support of both N+1 Singer and Investec as our joint brokers as we enter into this next phase of accelerated growth."

EKF Diagnostics Holdings plc

Christopher Mills, Non-executive Chairman
Julian Baines, CEO
Richard Evans, FD & COO

www.ekfdiagnostics.com

Tel: +44 (0)29 2071 0570

N+1 Singer (Nominated Adviser & Joint Broker) Tel: +44 (0)20 7496 3000

Aubrey Powell / George Tzimas / Tom Salvesen

Investec Bank plc (Joint Broker)

Gary Clarence / Daniel Adams

Tel: +44 (0)20 7597 4000

Walbrook PR Limited

Paul McManus / Lianne Cawthorne

Tel: +44 (0)20 7933 8780 or ekf@walbrookpr.com

Mob: +44 (0)7980 541 893 / +44 (0)7584 391 303

About EKF Diagnostics Holdings plc (www.ekfdiagnostics.com)

EKF is a leading point-of-care diagnostics and central laboratory assay manufacturer with an estimated 80,000 hemoglobin, hematocrit, HbA1c, glucose and lactate analysers in regular use across more than 100 countries. EKF specialises in developing tests for use in anemia and diabetes diagnosis and management, as well as providing a portfolio of reagents for use in clinical chemistry analysers.

EKF specialises in the development, production and worldwide distribution of point-of-care analyzers and clinical chemistry reagents for use in hospital and research laboratories, doctor's offices, blood banks and for in-field anaemia screening programmes. EKF is also a bulk manufacturer of enzymes and has custom

manufacturing facilities in the across sites in the US, UK and Europe for a variety of life science products. Demand for contract manufacturing of COVID-19 sample collection tests and kits has grown dramatically during the pandemic, however the capabilities can be applied to other areas of diagnostic testing, molecular disease and forensic test manufacture.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our [Privacy Policy](#).

END

APPZZGMVKGZGMZZ admin Change of Adviser 31920903 A Wed, 06/16/2021 - 07:00 LSE RNS
Executive Changes EKF